Ascent Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$319K Buy
8,683
+453
+6% +$21.5K 0.01% 607
2025
Q4
$419K Sell
8,230
-1,187
-13% -$60.7K 0.01% 532
2025
Q3
$523K Sell
9,417
-6,253
-40% -$366K 0.02% 494
2025
Q2
$1.08M Sell
15,670
-10,862
-41% -$739K 0.04% 318
2025
Q1
$1.84M Buy
26,532
+6,218
+31% +$514K 0.08% 246
2024
Q4
$1.75M Sell
20,314
-2,841
-12% -$307K 0.13% 193
2024
Q3
$2.76M Buy
23,155
+286
+1% +$38.1K 0.21% 126
2024
Q2
$3.26M Buy
22,869
+3,670
+19% +$486K 0.27% 94
2024
Q1
$2.47M Buy
19,199
+795
+4% +$94.6K 0.22% 131
2023
Q4
$2.22M Buy
18,404
+9,057
+97% +$896K 0.21% 134
2023
Q3
$935K Sell
9,347
-715
-7% -$63K 0.1% 239
2023
Q2
$952K Sell
10,062
-1,664
-14% -$136K 0.1% 242
2023
Q1
$933K Buy
11,726
+532
+5% +$37.7K 0.1% 242
2022
Q4
$757K Sell
11,194
-256
-2% -$15K 0.09% 249
2022
Q3
$623K Sell
11,450
-1,566
-12% -$83.9K 0.08% 258
2022
Q2
$755K Sell
13,016
-20
-0.2% -$1.11K 0.09% 243
2022
Q1
$724K Buy
13,036
+4,648
+55% +$239K 0.08% 257
2021
Q4
$400K Buy
+8,388
New +$454K 0.05% 334

Other funds holding NVO

Ascent Group's NVO Position: Q1 2026 in Review

Ascent Group increased its Novo Nordisk (NVO) stake by 5.5% in Q1 2026, buying an estimated $21.5K and bringing the position to 8,683 shares worth $319K. The position accounts for 0.01% of the portfolio, ranked #607.

Ascent Group first reported a position in NVO in Q4 2021 and has held it in 18 quarters since. The position peaked at $3.26M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Ascent Group held 8,683 shares of Novo Nordisk worth $319K as of Q1 2026.
  • Ascent Group bought 453 Novo Nordisk shares in Q1 2026, an estimated $21.5K.
  • Novo Nordisk made up 0.01% of Ascent Group's portfolio in Q1 2026, its #607 holding.
  • Ascent Group first reported a position in Novo Nordisk in Q4 2021 and has held it in 18 quarters since.
  • Ascent Group's Novo Nordisk position peaked at $3.26M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.